Bespak and Aesica unveil new single source supply chain solution for drug delivery device and pharmaceutical manufacturing services

Bespak and Aesica unveil new single source supply chain solution for drug delivery device and pharmaceutical manufacturing services

Novel business model set to streamline and speed products to market whilst reducing cost and complexity of development

11 November 2015:- Bespak, a world leading drug delivery device design, development and manufacturing company and Aesica, a global pharmaceutical contract development and manufacturing organisation (CDMO), are today unveiling the industry's first single source supply chain solution for drug delivery products incorporating formulation development, device design and development, drug and device manufacture, fill/finish and secondary packaging. This new business model has been brought to the market following Consort Medical's acquisition of Aesica.

Consort Medical has combined and integrated Aesica's drug formulation, manufacturing and packaging capabilities with Bespak's market leading drug delivery device, design, development and manufacturing services. This has created a global single source drug and device contract manufacturing partner for pharmaceutical customers. The full range of services that the Group now provides includes inhalation, nasal, ocular, Buccal, and transdermal drug delivery device concept generation, design, development, and manufacture at pilot through to high volume commercial scale, as well as API and formulation development and manufacture and finished dose fill/finish.

Bespak and Aesica have strong synergies and similarities across quality control, regulatory compliance and reliable manufacturing. This includes QP release and ISO certified Quality Management Systems, cGMP compliance and operating to FDA and MHRA standards of approval. Furthermore, both companies comply with environmental and health and safety standards. Aesica provides secure facilities that handle up to schedule 2 controlled substances, together with a high containment suite capable of manufacturing products in the SafeBridge category 3 potency level.

Both brands provide pilot up to volume manufacturing – operating at scales from low volume pilot manufacture to very high volume automated production operations and from grams to full scale manufacture of drugs. In addition, continuous improvement tools underpin each company's operations. Moreover, Bespak and Aesica offer complex solutions and capabilities ranging from better than 6-sigma manufacturing operations at Bespak through to semi continuous processing, high capacity and high potent drug manufacturing at Aesica.

About Consort Medical:

·        Consort Medical plc is a leading, global, single source drug and delivery device CDMO through its two operating subsidiaries Bespak and Aesica. Consort Medical is at the leading edge of innovation and is committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities

About Bespak:

·        Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectables products, and the manufacture of devices for the point of care diagnostics market.

About Aesica

·        Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners.

For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: +44 (0) 20 3 735 8168 or e-mail; [email protected]

 

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.